» Articles » PMID: 31197461

Clinicopathological Implications of TIM3 Tumor-infiltrating Lymphocytes and the MiR-455-5p/Galectin-9 Axis in Skull Base Chordoma Patients

Overview
Date 2019 Jun 15
PMID 31197461
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Chordoma is difficult to eradicate due to high local recurrence rates. The immune microenvironment is closely associated with tumor prognosis; however, its role in skull base chordoma is unknown. The expression of Galectin-9 (Gal9) and tumor-infiltrating lymphocyte (TIL) markers was assessed by immunohistochemistry. Kaplan-Meier and multivariate Cox analyses were used to assessing local recurrence-free survival (LRFS) and overall survival (OS) of patients. MiR-455-5p was identified as a regulator of Gal9 expression. Immunopositivity for Gal9 was associated with tumor invasion (p = 0.019), Karnofsky performance status (KPS) score (p = 0.017), and total TIL count (p < 0.001); downregulation of miR-455-5p was correlated with tumor invasion (p = 0.017) and poor prognosis; and the T-cell immunoglobulin and mucin-domain 3 (TIM3) TIL count was associated with chordoma invasion (p = 0.010) and KPS score (p = 0.037). Furthermore, multivariate analysis indicated that only TIM3 TIL density was an independent prognostic factor for LRFS (p = 0.010) and OS (p = 0.016). These results can be used to predict clinical outcome and provide a basis for immune therapy in skull base chordoma patients.

Citing Articles

TIM proteins and microRNAs: distinct impact and promising interactions on transplantation immunity.

Tao J, Shen X, Qian H, Ding Q, Wang L Front Immunol. 2024; 15:1500228.

PMID: 39650660 PMC: 11621082. DOI: 10.3389/fimmu.2024.1500228.


Immune microenvironment and immunotherapy for chordoma.

Chen Y, Zhang H Front Oncol. 2024; 14:1374249.

PMID: 38983929 PMC: 11232415. DOI: 10.3389/fonc.2024.1374249.


The prognostic and immune significance of PLBD1 in pan-cancer and its roles in proliferation and invasion of glioma.

Wei M, Zhou G, Chen L, Zhang Y, Ma W, Gao L J Cancer. 2024; 15(12):3857-3872.

PMID: 38911364 PMC: 11190780. DOI: 10.7150/jca.96365.


Animal model considerations for chordoma research: reproducing the tumor microenvironment with humanized mice.

Campilan B, Schroeder C, Sagaityte E, Arditi J, Leary O, Ziya L Gokaslan Front Oncol. 2024; 14:1330254.

PMID: 38544830 PMC: 10965562. DOI: 10.3389/fonc.2024.1330254.


Dysregulation of noncoding RNA in chordoma; implications in identifying potential targets for novel therapeutic approaches.

Ghosh P, Ghosh A Mol Biol Rep. 2024; 51(1):125.

PMID: 38236360 DOI: 10.1007/s11033-023-09017-9.


References
1.
Lim M, Xia Y, Bettegowda C, Weller M . Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol. 2018; 15(7):422-442. DOI: 10.1038/s41571-018-0003-5. View

2.
Wong N, Wang X . miRDB: an online resource for microRNA target prediction and functional annotations. Nucleic Acids Res. 2014; 43(Database issue):D146-52. PMC: 4383922. DOI: 10.1093/nar/gku1104. View

3.
Han G, Chen G, Shen B, Li Y . Tim-3: an activation marker and activation limiter of innate immune cells. Front Immunol. 2013; 4:449. PMC: 3857553. DOI: 10.3389/fimmu.2013.00449. View

4.
Shang B, Liu Y, Jiang S, Liu Y . Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep. 2015; 5:15179. PMC: 4604472. DOI: 10.1038/srep15179. View

5.
Zou M, Peng A, Lv G, Wang X, Li J, She X . Expression of programmed death-1 ligand (PD-L1) in tumor-infiltrating lymphocytes is associated with favorable spinal chordoma prognosis. Am J Transl Res. 2016; 8(7):3274-87. PMC: 4969465. View